Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Dec 17;79(6):1468-1471.
doi: 10.1093/cid/ciae242.

Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Lena van der Wekken-Pas  1 , Fabian Weiss  2 , Charlotte Simon-Zuber  2 , Rena Sebisch  2 , Carmen Wiese  3 , Elisabeth van Leeuwen  4 , David Burger  1 , Angela Colbers  1
Affiliations
Case Reports

Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Lena van der Wekken-Pas et al. Clin Infect Dis. .

Abstract

This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.

Keywords: HIV; cabotegravir; long-acting injectables; pregnancy; rilpivirine.

PubMed Disclaimer

Conflict of interest statement

Potential conflicts of interest. L. v. d. W. P. received research grants from Merck and honorarium for lectures from ViiV Healthcare, all paid to the institution. D. B. received research grants and honorarium for lectures from ViiV Healthcare, all paid to the institution. A. C. received research grants from ViiV Healthcare, Gilead, Merck, all paid to the institution. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Figures

Figure 1.
Figure 1.
Concentrations of cabotegravir (CAB) and rilpivirine (RPV) on a semilog scale, including infant CAB (indicated by x), infant RPV (open triangle), maternal CAB (open circles), and maternal RPV (black triangles) concentrations. The timing of injections is depicted below the graph. (Threshold levels derived from Thoueille et al [6] and Cutrell et al [7]. Abbreviation: GA, gestational age; PA-IC90, protein-adjusted 90% inhibitory concentration.
See this image and copyright information in PMC

References

    1. Department of Health and Human Services (DHHS) . Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States 2023. Updated 31 January 2024. Available at: https://clinicalinfo.hiv.gov/en/guidelines/perinatal/whats-new-guidelines. Accessed November 2023.
    1. Patel P, Ford SL, Baker M, et al. Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long-acting cabotegravir and rilpivirine in clinical trials. HIV Med 2023; 24:568–79. - PubMed
    1. Delany-Moretlwe S, Hughes JP, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet 2022; 399:1779–89. - PMC - PubMed
    1. D'Amico R, Cenoz Gomis S, Moodley R, et al. Compassionate use of long-acting cabotegravir plus rilpivirine for people living with HIV-1 in need of parenteral antiretroviral therapy. HIV Med 2023; 24:202–11. - PubMed
    1. Committee Antiretroviral Pregnancy Registry (APR) . Antiretroviral Pregnancy Registry international interim report for 1 January 1989–31 January 2021. Available at: http://www.apregistry.com/forms/interim_report.pdf. Accessed November 2023.

Publication types

MeSH terms